Found this article with the CEO of Alfasigma talki
Post# of 72440
(Total Views: 370)
Posted On: 09/05/2019 8:57:45 AM
Found this article with the CEO of Alfasigma talking about IPIX. As it was in Italian it read like this.
L'accordo infatti include anche un diritto di prelazione per Brilacidin nel trattamento di forme più estese di malattie infiammatorie croniche intestinali (MICI), come la colite ulcerosa e la malattia di Crohn e un diritto di prima negoziazione per Brilacidin in altre indicazioni gastro-intestinali. Oltre a un esborso iniziale, l’accordo prevede una serie di pagamenti aggiuntivi basati su determinate milestones, per un totale di oltre $ 24 milioni e royalties del 6% sulle vendite nette nella commercializzazione di Brilacidin per PU/PSU.
Translated it seems as he states they paid more than 24 million euros.
The agreement also includes a right of preemption for Brilacidin in the treatment of more extensive forms of chronic inflammatory bowel disease (MICI), such as ulcerative colitis and Crohn's disease, and a right of first negotiation for Brilacidin in other gastro-intestinal indications. In addition to an initial outlay, the agreement provides for a series of additional payments based on certain milestones, totaling more than 24 million euros and royalties of 6% on net sales in the marketing of Brilacidin for PU/PSU
If this is the case we got more than 26.5 million, the article also references him say an initial out lay of $.
L'accordo infatti include anche un diritto di prelazione per Brilacidin nel trattamento di forme più estese di malattie infiammatorie croniche intestinali (MICI), come la colite ulcerosa e la malattia di Crohn e un diritto di prima negoziazione per Brilacidin in altre indicazioni gastro-intestinali. Oltre a un esborso iniziale, l’accordo prevede una serie di pagamenti aggiuntivi basati su determinate milestones, per un totale di oltre $ 24 milioni e royalties del 6% sulle vendite nette nella commercializzazione di Brilacidin per PU/PSU.
Translated it seems as he states they paid more than 24 million euros.
The agreement also includes a right of preemption for Brilacidin in the treatment of more extensive forms of chronic inflammatory bowel disease (MICI), such as ulcerative colitis and Crohn's disease, and a right of first negotiation for Brilacidin in other gastro-intestinal indications. In addition to an initial outlay, the agreement provides for a series of additional payments based on certain milestones, totaling more than 24 million euros and royalties of 6% on net sales in the marketing of Brilacidin for PU/PSU
If this is the case we got more than 26.5 million, the article also references him say an initial out lay of $.
(2)
(0)Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
Scroll down for more posts ▼